ACHNYSEWholesale-Medical, Dental & Hospital Equipment & SuppliesFiscal year ends December 31
ACCENDRA HEALTH INC/VA/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.22−0.01 (-6.30%)
Close on Oct 19, 2026
- Market cap
- $16.89M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
46.7%+31.6 pts over 5 years
Operating margin
1.0%−1.4 pts over 5 years
Net margin
-39.8%−40.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.1% | -34.8% | -20.1% | -11.9% | |
| Gross profit | -41.9% | -11.0% | +0.1% | +0.6% | |
| Operating income | – | -42.3% | -33.0% | -18.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 5.1% | -1755.6% | |
| Return on assets | 4.0% | 0.9% | -31.0% | |
| Current ratio | 1.90 | 1.59 | 0.58 | |
| Debt to equity | 0.59 | 1.44 | -4.45 | |
| Net debt to EBITDA | 1.51× | 3.00× | 7.31× | |
| Interest coverage | 7.4× | 2.4× | 0.3× | |
| Inventory turnover | 9.2× | 6.1× | 20.7× | |
| Capex to revenue | 0.2% | 0.6% | 6.9% | |
| Diluted shares | 61M | 64M | 77M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Accendra Health generated $1.45B from operations and spent $743.60M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$1.45B
Used
$743.60M
Capital expenditure$732.69M99%Dividends$731.00K0%Share buybacks$10.18M1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39.8%
×Asset turnover0.78×
×Equity multiplier56.69×
=Return on equity, FY2025-1755.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -39.8% | 0.78× | 56.69× | -1755.6% |
| FY2024 | -13.5% | 0.55× | 6.37× | -47.4% |
| FY2023 | -1.6% | 0.49× | 5.48× | -4.3% |
| FY2022 | 0.2% | 2.23× | 4.68× | 2.4% |
| FY2021 | 2.3% | 2.85× | 4.16× | 26.9% |
| FY2020 | 0.4% | 2.43× | 5.94× | 5.1% |
| FY2019 | -0.7% | 2.48× | 7.56× | -12.7% |
| FY2018 | -4.6% | 2.63× | 4.66× | -57.0% |
| FY2017 | 0.8% | 3.06× | 3.08× | 7.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.10B
- Cash generatingOperating cash flow above zero-$101.79M
- Return on assets improvedROA up on the prior year-7.1% → -23.6%
- Earnings backed by cashOperating cash flow above net income-$101.79M vs -$1.10B
- Less leverageLong-term debt to assets fell38.6% → 73.4%
- Better liquidityCurrent ratio rose1.09 → 0.58
- No dilutionShare count did not rise77M → 77M
- Gross margin improvedGross margin up on the prior year82.80% → 46.68%
- More efficientAsset turnover rose0.53 → 0.59